Stemcell United Stock

Stemcell United ROE

The Return on Equity (ROE) of Stemcell United (SCU.AX) as of Sep 9, 2026 is -121.22 %. In the previous year, Return on Equity (ROE) was -50.73 % — a change of 138.93% (lower).

ROE

-121.22 %

YoY

138.93%

Last updated:

In 2026, Stemcell United's return on equity (ROE) was -121.22 %, a 138.93% increase from the -50.73 % ROE in the previous year.

The Stemcell United ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
50,077.57 AUD
Jan 1, 2016
-857.33 AUD
Jan 1, 2017
-170.94 AUD
Jan 1, 2018
-279.29 AUD
Jan 1, 2019
-134.17 AUD
Jan 1, 2020
-314.86 AUD
Jan 1, 2021
-50.73 AUD
Jan 1, 2022
-121.22 AUD
The Stemcell United ROE history
YEARROEYoY
-121.22 %+138.93%
-50.73 %-83.89%
-314.86 %+134.67%
-134.17 %-51.96%
-279.29 %+63.39%
-170.94 %-80.06%
-857.33 %-101.71%
50,077.57 %—
Access this data via the Eulerpool API
Get Free API Key

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

ROE Details

Decoding Stemcell United's Return on Equity (ROE)

Stemcell United's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Stemcell United's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Stemcell United's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Stemcell United’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Stemcell United stock

Return on Equity (ROE) of Stemcell United is -121.22 % in 2026.

Return on Equity (ROE) of Stemcell United changed from -50.73 % to -121.22 %, representing a 138.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Stemcell United since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Stemcell United with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Stemcell United

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Stemcell United